Mitomycin Substipharm: Uses, Dosage & Side Effects
An antineoplastic antibiotic used intravesically for the treatment and prevention of recurrence of non-muscle-invasive bladder cancer (NMIBC) following transurethral resection
Mitomycin Substipharm contains the active substance mitomycin, a cytotoxic antibiotic originally derived from the bacterium Streptomyces caespitosus. This specific formulation is designed exclusively for intravesical use – direct instillation into the urinary bladder via a catheter – to treat and prevent recurrence of non-muscle-invasive bladder cancer (NMIBC). Mitomycin works by cross-linking DNA strands inside cancer cells, preventing them from dividing and ultimately causing cell death. When administered intravesically, the drug acts locally on the bladder lining with minimal systemic absorption, reducing the risk of widespread side effects. Mitomycin Substipharm is one of the most widely used intravesical chemotherapy agents worldwide, recommended by major urological guidelines including the European Association of Urology (EAU), American Urological Association (AUA), and National Comprehensive Cancer Network (NCCN).
Quick Facts: Mitomycin Substipharm
Key Takeaways
- Mitomycin Substipharm is specifically formulated for intravesical use (instillation directly into the bladder) and must not be given intravenously; it is used to treat and prevent recurrence of non-muscle-invasive bladder cancer after transurethral resection.
- A single immediate post-operative instillation within 6 hours of TURBT is recommended by international guidelines for low- and intermediate-risk NMIBC and has been shown to reduce recurrence rates by approximately 40% compared with TURBT alone.
- The drug works by cross-linking DNA in cancer cells on the bladder wall; systemic absorption through intact urothelium is minimal, which means fewer whole-body side effects compared with intravenous chemotherapy.
- The most common side effects are local: chemical cystitis (bladder irritation), painful urination, urinary frequency, and contact dermatitis on the hands or genitalia from mitomycin in the urine.
- Mitomycin must not be instilled if bladder perforation is suspected, if there is significant post-operative bleeding, or within 1–2 weeks of a traumatic catheterisation, as systemic absorption through a damaged bladder wall can cause serious myelosuppression.
What Is Mitomycin Substipharm and What Is It Used For?
Mitomycin Substipharm contains mitomycin, one of the most thoroughly studied intravesical chemotherapy agents in urological oncology. Mitomycin is a natural product originally isolated from the soil bacterium Streptomyces caespitosus in the 1950s. It belongs to the class of antineoplastic antibiotics and functions as a bioreductive alkylating agent. After enzymatic reduction within cells, mitomycin forms highly reactive species that create cross-links between complementary DNA strands (inter-strand cross-links) as well as within the same strand (intra-strand cross-links). These cross-links physically prevent the DNA double helix from separating during replication, effectively blocking cell division and leading to programmed cell death (apoptosis). The cytotoxic activity of mitomycin is not cell-cycle specific, meaning it can kill cells regardless of which phase of the cell cycle they are in, although cells in late G1 and early S phase are particularly sensitive.
The Substipharm formulation is designed exclusively for intravesical administration. This means the drug is dissolved in a solvent and instilled directly into the urinary bladder through a urethral catheter. The solution remains in contact with the bladder wall for a defined dwell time (typically 1 to 2 hours), during which mitomycin penetrates the superficial layers of the urothelium (the inner lining of the bladder) and destroys residual cancer cells. Because the molecular weight of mitomycin (334 Da) and its chemical properties limit absorption through the intact bladder wall, systemic drug levels remain very low during intravesical therapy. This localized delivery is one of the principal advantages of intravesical mitomycin: the drug achieves high concentrations at the tumour site while producing minimal systemic toxicity.
Bladder cancer is one of the most common cancers worldwide, with approximately 615,000 new cases and 220,000 deaths annually according to GLOBOCAN data. About 75% of newly diagnosed bladder cancers are non-muscle-invasive at presentation, confined to the mucosa (stage Ta or carcinoma in situ) or lamina propria (stage T1). The standard initial treatment for visible NMIBC is transurethral resection of bladder tumour (TURBT), which surgically removes the tumour under cystoscopic guidance. However, NMIBC has a notoriously high recurrence rate – without adjuvant treatment, approximately 50–70% of patients will experience tumour recurrence within five years, and 10–30% will progress to muscle-invasive disease.
Intravesical therapy with mitomycin is a cornerstone strategy for reducing this recurrence risk. Multiple randomized controlled trials and meta-analyses have established its efficacy in two main clinical settings:
- Single immediate post-operative instillation: A single dose of intravesical mitomycin administered within 6 hours (ideally within 2 hours) of TURBT has been shown in a landmark meta-analysis by Sylvester et al. (2004, updated 2016) to reduce the relative risk of tumour recurrence by approximately 40% compared with TURBT alone. This approach is recommended for patients with low-risk and intermediate-risk NMIBC by the EAU, AUA, and NCCN guidelines. The mechanism is believed to involve destruction of floating tumour cells released during surgery and chemoresection of residual microscopic disease at the resection site and elsewhere in the bladder.
- Adjuvant intravesical course therapy: For intermediate-risk NMIBC, a course of weekly intravesical mitomycin instillations (induction phase) followed by optional monthly maintenance instillations provides further reduction in recurrence risk. The EORTC 30831 and other trials have demonstrated that course therapy offers additional benefit beyond immediate instillation alone, particularly for patients with multiple or recurrent tumours.
Mitomycin is considered the preferred intravesical chemotherapy agent by many guidelines due to its well-established efficacy profile, extensive clinical evidence base spanning decades, and favourable local tolerability compared with some other intravesical chemotherapy agents. For high-risk NMIBC, including T1 tumours and carcinoma in situ, intravesical BCG (Bacillus Calmette-Guérin) immunotherapy is generally preferred over mitomycin due to superior efficacy in preventing both recurrence and progression; however, mitomycin remains an important alternative when BCG is unavailable, contraindicated, or when BCG treatment fails in selected patients.
Mitomycin Substipharm is formulated specifically for intravesical instillation into the bladder. It must not be administered intravenously, intramuscularly, subcutaneously, or by any other route. While mitomycin is used intravenously in other formulations for different cancer types, the Substipharm intravesical formulation has specific reconstitution instructions and is packaged accordingly. Always verify the correct product and route of administration before use.
What Should You Know Before Receiving Mitomycin Substipharm?
Contraindications
There are specific situations in which Mitomycin Substipharm must not be administered. Your urologist will carefully assess each of these before proceeding with intravesical instillation.
- Hypersensitivity: Do not receive mitomycin if you are allergic to mitomycin or any of the other ingredients in the product.
- Bladder perforation: Mitomycin must not be instilled if perforation of the bladder wall is suspected or confirmed during or after TURBT. Perforation would allow direct entry of the drug into the peritoneal cavity or systemic circulation, potentially causing severe toxicity.
- Active urinary tract infection: The presence of an active urinary tract infection increases the risk of systemic absorption and may exacerbate local bladder irritation. Treatment should be deferred until the infection is resolved.
- Significant haematuria: Visible blood in the urine after surgery suggests mucosal disruption, which increases the risk of systemic mitomycin absorption. Instillation should be delayed until haematuria resolves.
- Traumatic catheterisation: If catheter insertion is traumatic or difficult, instillation should not proceed, as urethral or bladder trauma can provide a route for systemic drug absorption.
- Pregnancy and breastfeeding: Mitomycin is teratogenic and mutagenic. It must not be used during pregnancy or breastfeeding.
Warnings and Precautions
If mitomycin is absorbed systemically through a damaged bladder wall (due to perforation, traumatic catheterisation, or extensive TURBT), it can cause severe bone marrow suppression (myelosuppression) leading to dangerously low blood counts. This includes neutropenia, thrombocytopenia, and anaemia, which can be life-threatening. Blood counts must be monitored if systemic absorption is suspected, and the patient should be referred for urgent haematological assessment.
Before and during treatment with intravesical mitomycin, your healthcare team should be aware of the following precautions:
- Timing after TURBT: For immediate post-operative instillation, many guidelines recommend waiting at least until macroscopic haematuria has cleared. If the resection was extensive, deep, or if perforation cannot be ruled out, instillation should be postponed for 1–2 weeks to allow the bladder wall to heal.
- Bladder capacity: Patients with significantly reduced bladder capacity may not tolerate the instilled volume and dwell time. The treatment team should assess whether the patient can comfortably retain the solution for the required period.
- Skin contact precautions: Mitomycin in the urine can cause contact dermatitis, particularly on the hands, genitalia, and perineal area. Patients should be advised to wash their hands thoroughly after voiding and to avoid skin contact with their urine during and for several hours after each instillation. Sitting in a bath after voiding should be avoided.
- Renal function: Although systemic absorption is minimal with intact urothelium, patients with impaired renal function may be at higher risk of toxicity if unexpected systemic absorption occurs. Renal function should be assessed before treatment.
- Hepatic function: Similarly, hepatic impairment may affect the metabolism of any systemically absorbed mitomycin. Liver function should be assessed before initiating treatment.
- Blood count monitoring: Routine monitoring of full blood counts is recommended during a course of intravesical mitomycin therapy, particularly if there is any suspicion of systemic absorption. Any unexplained drops in blood counts should prompt immediate investigation.
- Bladder contracture: Prolonged courses of intravesical mitomycin (particularly beyond the standard induction and maintenance schedule) have been associated with reduced bladder capacity (contracted bladder). Patients should be monitored for increasing urinary frequency and decreasing voided volumes during maintenance therapy.
- Handling precautions for healthcare workers: Mitomycin is a cytotoxic agent. Healthcare professionals preparing and administering the solution must follow institutional cytotoxic handling guidelines, including the use of protective gloves, gowns, and eye protection. Preparation should occur in a designated area, ideally a biological safety cabinet.
Pregnancy and Breastfeeding
Mitomycin has demonstrated teratogenic, mutagenic, and embryotoxic effects in preclinical studies. It must not be administered during pregnancy. Women of childbearing potential should use effective contraception during treatment and for an appropriate period after the last instillation, as advised by their urologist. Men receiving intravesical mitomycin should also be counselled about potential genotoxic effects and should use effective contraception during and for a period after treatment.
It is not known whether mitomycin or its metabolites are excreted in human breast milk following intravesical administration. Given the cytotoxic nature of the drug and the theoretical risk of harm to the nursing infant, breastfeeding must be discontinued during treatment with Mitomycin Substipharm.
Driving and Operating Machinery
Intravesical mitomycin is not expected to have a significant direct effect on the ability to drive or operate machinery, as systemic absorption is minimal. However, the procedure itself (catheterisation, the need to retain the solution, and subsequent voiding) may cause temporary discomfort, urgency, or dysuria that could affect concentration. Patients should be advised to avoid driving immediately after the instillation procedure if they experience significant urinary symptoms.
How Does Mitomycin Substipharm Interact with Other Drugs?
Drug interactions with intravesical mitomycin are fundamentally different from those associated with systemic (intravenous) mitomycin administration. Because the Substipharm formulation is designed for local bladder instillation and systemic absorption through intact urothelium is minimal, the risk of pharmacokinetic interactions (changes in drug metabolism or blood levels) is very low under normal circumstances. However, there are important considerations that your medical team will take into account.
Major Interactions
| Interacting Drug/Agent | Effect | Clinical Significance |
|---|---|---|
| Pelvic radiotherapy | Increased risk of bladder mucosal damage, haematuria, reduced bladder capacity; radiation may increase urothelial permeability allowing greater mitomycin absorption | Coordinate timing carefully; avoid concurrent use or ensure adequate interval between radiation and instillation |
| Other systemic myelosuppressive agents (e.g., cytotoxic chemotherapy) | Additive bone marrow suppression if mitomycin is inadvertently absorbed systemically | Monitor blood counts more frequently; ensure bladder integrity before instillation |
| Live vaccines (e.g., MMR, varicella, BCG) | Risk of vaccine-strain infection if patient becomes immunosuppressed due to unexpected systemic absorption | Avoid live vaccines during intravesical treatment courses as a precaution |
| Intravesical BCG | The two agents should not be mixed or given simultaneously; sequential use requires an appropriate interval | If switching from mitomycin to BCG (or vice versa), allow at least 1–2 weeks between instillations |
Minor Interactions
| Interacting Drug/Agent | Effect | Clinical Significance |
|---|---|---|
| Anticoagulants (warfarin, DOACs) | May increase the risk of post-TURBT bleeding, which can delay mitomycin instillation | Perioperative anticoagulation management per institutional protocols; delayed instillation if bleeding is significant |
| Anticholinergic medications | May reduce bladder spasms during dwell time, potentially improving tolerability | Sometimes used intentionally to help patients retain the instillation for the full dwell time |
| Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) | Theoretical increased toxicity risk if unexpected systemic mitomycin absorption occurs and renal clearance is impaired | Monitor renal function; generally not a concern with intact bladder mucosa |
| Sodium bicarbonate (urinary alkalinizer) | Alkalinization of urine may improve mitomycin stability and activity at the bladder surface | Some protocols include pre-treatment oral sodium bicarbonate to optimize intravesical drug pH |
It is important to inform your urologist about all medications you are taking, including over-the-counter drugs, herbal supplements, and vitamins. Although the risk of systemic drug interactions with intravesical mitomycin is low, your medical team needs a complete medication list to manage your overall care safely, particularly in the perioperative period around TURBT.
What Is the Correct Dosage of Mitomycin Substipharm?
Mitomycin Substipharm is always prepared and administered by trained healthcare professionals in a hospital or clinic setting. The drug is supplied as a powder that must be reconstituted with the provided solvent before use. The reconstituted solution is instilled into the bladder through a urinary catheter. Your urologist will determine the most appropriate dosing schedule based on your tumour risk category, the extent of surgery performed, and your individual clinical circumstances.
Immediate Post-Operative Instillation
Single Dose After TURBT
Indication: Low-risk and intermediate-risk NMIBC (single small papillary Ta, low grade)
Dose: 40 mg mitomycin dissolved in 40 mL solvent (1 mg/mL concentration)
Timing: Within 6 hours of TURBT; ideally within 2 hours for maximum benefit
Dwell time: 1 hour (range 30 minutes to 2 hours depending on protocol)
Preconditions: No suspected perforation, no significant haematuria, no traumatic catheterisation
The patient should change position every 15 minutes (supine, left side, right side, prone) to ensure the solution contacts all surfaces of the bladder. After the dwell time, the catheter is opened to drain the solution, or the patient voids normally.
Adjuvant Intravesical Course Therapy
Induction Course
Indication: Intermediate-risk NMIBC; patients who have received an immediate instillation and remain at risk of recurrence
Dose: 20–40 mg mitomycin dissolved in 20–40 mL solvent per instillation
Schedule: Once weekly for 6–8 consecutive weeks, starting 2–6 weeks after TURBT (once the bladder has healed)
Dwell time: 1–2 hours per instillation
Maintenance Course
Indication: Patients who have completed induction and are considered to benefit from continued prophylaxis
Dose: 20–40 mg per instillation
Schedule: Once monthly for up to 12 months (total treatment duration including induction)
Monitoring: Cystoscopy at regular intervals (typically every 3 months for the first 2 years) to assess tumour recurrence
The optimal duration of maintenance therapy remains a subject of ongoing research. Some protocols use shorter maintenance courses (3–6 months), while others extend to 12 months. Your urologist will tailor the duration based on your risk profile and tolerance of treatment.
Dose Optimisation Strategies
Several evidence-based strategies can improve the efficacy of intravesical mitomycin:
- Fluid restriction: Patients are advised to restrict fluid intake for 6–8 hours before instillation to reduce urine production and avoid diluting the drug within the bladder.
- Urinary alkalinisation: Oral sodium bicarbonate (e.g., 1.5 g the evening before and morning of treatment) can raise urinary pH, improving mitomycin stability and activity. Mitomycin is most active at pH 6–8 and degrades rapidly in acidic urine.
- Complete bladder emptying: The bladder should be emptied completely via catheter before instillation to avoid dilution of the drug.
- Adequate dwell time: The drug must remain in contact with the bladder wall for at least 1 hour, and up to 2 hours if tolerated, to maximise absorption into the urothelium.
- Positional changes: Patients should rotate between different body positions during the dwell time to ensure all bladder surfaces receive drug contact.
Children
Intravesical mitomycin is not indicated for use in children. Bladder cancer is exceedingly rare in the paediatric population. The safety and efficacy of intravesical Mitomycin Substipharm in patients under 18 years of age have not been established.
Elderly Patients
There is no specific dose adjustment required for elderly patients based on age alone. However, older patients may have reduced bladder capacity, a higher prevalence of urinary tract infections, and more fragile bladder mucosa. These factors should be considered when planning intravesical therapy. The urologist may choose to use a lower instillation volume or shorter dwell time in selected elderly patients to improve tolerability.
Missed Dose
If you miss a scheduled intravesical instillation during a course of treatment, contact your urology clinic to reschedule as soon as possible. A single missed instillation is unlikely to significantly compromise the overall treatment course, but the schedule should be resumed promptly. Do not attempt to “double up” on instillations to make up for a missed session.
Overdose
Overdose with intravesical mitomycin is unlikely under supervised hospital administration. If a higher-than-intended dose is instilled, the bladder should be irrigated with saline to remove as much drug as possible. The patient should be monitored closely for signs of increased local toxicity (severe cystitis, haematuria) and for any evidence of systemic absorption (bone marrow suppression). There is no specific antidote for mitomycin. Supportive care and haematological monitoring are the mainstay of management in such cases.
Mitomycin Substipharm is always prepared and administered by trained healthcare professionals in a hospital or specialised urology clinic. You will not self-administer this medication at home. Each instillation is carefully timed and monitored to ensure safety and efficacy.
What Are the Side Effects of Mitomycin Substipharm?
Because Mitomycin Substipharm is administered directly into the bladder and systemic absorption through intact urothelium is minimal, the side effect profile is predominantly local. The frequency and severity of local side effects tend to increase with the number of instillations received – patients undergoing a full course of induction and maintenance therapy typically experience more pronounced symptoms than those receiving a single post-operative instillation. Your urology team will monitor you throughout treatment and can adjust the schedule, dose, or dwell time if side effects become troublesome.
Local Bladder Side Effects
Very Common
May affect more than 1 in 10 people
- Chemical cystitis (bladder inflammation and irritation)
- Dysuria (painful or burning sensation during urination)
- Urinary frequency (needing to urinate more often than usual)
- Urinary urgency (sudden compelling need to urinate)
- Nocturia (waking at night to urinate)
Common
May affect up to 1 in 10 people
- Haematuria (blood in the urine, typically microscopic but occasionally visible)
- Suprapubic pain or bladder discomfort
- Contact dermatitis on hands, genitalia, or perineal area (from mitomycin in urine)
- Skin rash on palms (palmar dermatitis)
- Genital rash or erythema
Uncommon
May affect up to 1 in 100 people
- Reduced bladder capacity (bladder contracture) with prolonged use
- Urethritis (inflammation of the urethra)
- Bladder ulceration
- Allergic reaction localised to the bladder mucosa
- Calcification at instillation sites (rare with standard dosing)
Rare
May affect up to 1 in 1,000 people
- Severe bladder fibrosis and permanent reduced bladder capacity
- Necrosis of the bladder wall (extremely rare, usually associated with perforation or overdose)
- Ureteral obstruction due to oedema or fibrosis at the ureteral orifices
Systemic Side Effects (If Absorbed)
Systemic side effects are uncommon with proper intravesical administration through an intact bladder wall. However, if mitomycin is absorbed systemically – for example, through a perforated or damaged bladder – the following effects may occur:
Uncommon (Systemic)
Usually only if significant systemic absorption occurs
- Myelosuppression (bone marrow suppression): neutropenia, thrombocytopenia, anaemia
- Nausea and vomiting
- Fatigue and malaise
- Fever
Rare (Systemic)
Very rare with correct intravesical use
- Pulmonary toxicity (interstitial pneumonitis)
- Haemolytic uraemic syndrome (HUS)
- Renal toxicity
- Hepatotoxicity (liver damage)
- Mucositis (oral or gastrointestinal ulceration)
- Alopecia (hair loss)
Contact your urologist or seek emergency care if you experience: severe or persistent haematuria (heavy blood in the urine), inability to urinate, high fever after an instillation, signs of infection (fever, chills, malaise), severe abdominal pain, or unusual bruising or bleeding (which may indicate myelosuppression from unexpected systemic absorption).
The majority of local side effects resolve within a few days of each instillation and tend to be manageable with supportive measures such as increased fluid intake after the dwell period, anticholinergic medications for urgency and frequency, and topical barrier creams for contact dermatitis. Your urology team can advise on appropriate symptom management. If local toxicity becomes severe, the treatment course may need to be modified, delayed, or discontinued.
How Should Mitomycin Substipharm Be Stored?
Keep this medicine out of the sight and reach of children. Do not use after the expiry date stated on the vial label and outer carton after EXP. The expiry date refers to the last day of that month.
- Unopened vials: Store below 25°C (77°F). Do not freeze.
- Light protection: Keep the vial in the outer carton to protect from light.
- Reconstituted solution: The reconstituted intravesical solution should be used immediately after preparation. If not used immediately, the healthcare professional is responsible for ensuring in-use storage conditions and times are appropriate, typically no longer than 24 hours at 2–8°C.
- Inspection: Before use, the reconstituted solution should be inspected visually for particulate matter and discoloration. Do not use if the solution is not clear or contains visible particles.
As Mitomycin Substipharm is prepared and administered in a hospital or urology clinic, storage will be handled by your healthcare team and hospital pharmacy. Do not dispose of any medicines via wastewater or household waste. The healthcare team will ensure proper disposal of unused medicine and contaminated materials (catheters, drainage bags, protective equipment) in accordance with cytotoxic waste disposal protocols to protect the environment and personnel.
What Does Mitomycin Substipharm Contain?
Active Substance
The active substance is mitomycin (also known as mitomycin C). Each vial contains 20 mg of mitomycin as a lyophilised (freeze-dried) powder. Mitomycin is a cytotoxic antibiotic with a molecular weight of 334.33 Da, produced by the bacterium Streptomyces caespitosus. Its chemical structure includes an aziridine ring, a carbamate group, and a quinone moiety, which together are responsible for its alkylating and cross-linking activity after bioreductive activation within cells.
Solvent
The package includes a separate vial containing sterile sodium chloride 0.9% solution (normal saline) to be used as the solvent for reconstituting the mitomycin powder. The volume of solvent is designed to produce a solution at an appropriate concentration for intravesical instillation. The exact volume provided depends on the package configuration and target concentration specified in the prescribing information.
Appearance
Mitomycin Substipharm powder is a characteristic blue-violet to purple coloured lyophilised cake or powder. After reconstitution with the provided sodium chloride solvent, the resulting solution is a clear purple liquid suitable for intravesical instillation. The distinctive colour is inherent to the mitomycin molecule and is normal. Any solution that appears turbid, contains visible particles, or shows an unusual colour change should not be used.
Manufacturer
Mitomycin Substipharm is manufactured and marketed by Substipharm. The product is available in the European Union and other markets under the marketing authorisation of Substipharm or its regional affiliates. The manufacturing, quality control, and release of the product comply with European Good Manufacturing Practice (GMP) standards.
Frequently Asked Questions About Mitomycin Substipharm
Mitomycin Substipharm is used for intravesical instillation into the urinary bladder to treat and prevent recurrence of non-muscle-invasive bladder cancer (NMIBC). It is instilled directly into the bladder via a catheter, typically after transurethral resection of bladder tumours (TURBT). It can be given as a single immediate post-operative dose or as part of a multi-week course of adjuvant therapy. It is one of the most widely recommended intravesical chemotherapy agents by international urological guidelines.
The mitomycin powder is dissolved in the provided solvent and the resulting solution is instilled into the bladder through a urinary catheter by a trained healthcare professional. The solution is retained in the bladder for 1 to 2 hours, during which the patient is asked to change position periodically to ensure the drug contacts all surfaces of the bladder wall. After the dwell time, the solution is drained via the catheter or the patient voids normally. The procedure is performed in a hospital or urology clinic.
The catheterisation itself may cause mild discomfort, and some patients experience a sense of pressure or urgency while the solution is in the bladder. After the instillation, many patients report temporary burning during urination (dysuria), increased urinary frequency, and urgency for 24 to 48 hours. These symptoms are usually manageable with increased fluid intake and, if needed, anticholinergic or analgesic medications. Most patients tolerate the procedure well, particularly with repeated instillations as they become more familiar with the process.
If the bladder wall is perforated (has a hole), the mitomycin solution can leak into the peritoneal cavity or be absorbed directly into the bloodstream in large quantities. This can cause serious systemic toxicity, most critically severe bone marrow suppression (myelosuppression) leading to dangerously low blood cell counts. It can also cause chemical peritonitis (inflammation of the abdominal lining). This is why your urologist carefully assesses bladder integrity before every instillation and will postpone or cancel the treatment if perforation is suspected.
Intravesical mitomycin has been shown to significantly reduce bladder cancer recurrence. A single immediate post-operative instillation reduces the relative risk of tumour recurrence by approximately 40% compared with TURBT alone, according to a major meta-analysis. Course therapy (weekly induction followed by monthly maintenance) provides additional benefit for intermediate-risk patients. However, for high-risk NMIBC, intravesical BCG immunotherapy generally provides superior outcomes in terms of both recurrence prevention and, importantly, reduction in disease progression to muscle-invasive cancer.
Yes, intravesical mitomycin is typically an outpatient procedure. After the dwell period and voiding, most patients can go home the same day. You should wash your hands thoroughly after urinating for at least 6 hours after treatment to avoid skin contact with residual mitomycin in the urine. Some clinics recommend sitting rather than standing to urinate and cleaning the toilet thoroughly after use. You should drink plenty of fluids after the procedure to flush the bladder and dilute any remaining drug. Your urology team will provide specific instructions for post-treatment care at home.
References
- European Medicines Agency (EMA). Mitomycin Substipharm – Summary of Product Characteristics. Available from: EMA.
- Babjuk M, Burger M, Capoun O, et al. EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS). Eur Urol. 2025;87(1):1–18.
- Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder. Eur Urol. 2016;69(2):231–244.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2.2025.
- Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2024;211(1):11–36.
- Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001;21(1B):765–769.
- Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256.
- Au JL, Badalament RA, Wientjes MG, et al. Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial. J Natl Cancer Inst. 2001;93(8):597–604.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Witjes JA, Bruins HM, Cathómas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021;79(1):82–104.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in urology, oncology, and clinical pharmacology.
Medical Content
iMedic Urology Editorial Team – specialist physicians in urology with clinical experience in bladder cancer management and intravesical therapy
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, EAU, AUA, and NCCN guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and cytotoxic medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.